Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;14(1):e2022056.
doi: 10.4084/MJHID.2022.056. eCollection 2022.

Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients

Nicola Sgherza #  1 , Stefania Zucano #  2 , Angelantonio Vitucci  1 , Antonio Palma  1 , Francesco Tarantini  2 , Daniela Campanale  1 , Luigi Vimercati  3 , Angela Maria Vittoria Larocca  4 , Domenico Visceglie  5 , Amalia Acquafredda  5 , Angelo Ostuni  6 , Daniela Di Gennaro  2 , Carmen Vitucci  2 , Silvio Tafuri  7 , Pellegrino Musto  1   2
Affiliations

Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients

Nicola Sgherza et al. Mediterr J Hematol Infect Dis. .
No abstract available

Keywords: Anti-SARS-CoV-2 vaccine; Serological response; Transfusion-dependent thalassemia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no conflict of Interest.

Figures

Figure 1
Figure 1
Comparison of anti-SARS-CoV-2 spike IgG titer (AU/mL) between healthy controls (HC) and transfusion dependent thalassemia (TDT) patients (Mann Whitney test).
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467–478. - PMC - PubMed
    1. Longo F, Gianesin B, Voi V, Motta I, Pinto VM, Piolatto A, Spasiano A, Ruffo GB, Gamberini MR, Barella S, Mariani R, Fidone C, Rosso R, Casale M, Roberti D, Dal Zotto C, Vitucci A, Bonetti F, Pitrolo L, Quaresima M, Ribersani M, Quota A, Arcioni F, Campisi S, Massa A, De Michele E, Lisi R, Miano M, Bagnato S, Gentile M, Carrai V, Putti MC, Serra M, Gaglioti C, Migone De Amicis M, Graziadei G, De Giovanni A, Ricchi P, Balocco M, Quintino S, Borsellino Z, Fortini M, Denotti AR, Tartaglione I, Beccaria A, Marziali M, Maggio A, Perrotta S, Piperno A, Filosa A, Cappellini MD, De Franceschi L, Piga A, Forni GL. Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection. Am J Hematol. 2022 Feb 1;97(2):E75–E78. doi: 10.1002/ajh.26429. - DOI - PMC - PubMed
    1. Lee JX, Chieng WK, Lau SCD, Tan CE. COVID-19 and Hemoglobinopathies: A Systematic Review of Clinical Presentations, Investigations, and Outcomes. Front Med (Lausanne) 2021. - DOI - DOI - PMC - PubMed